FY2029 Earnings Estimate for CNTB Issued By Leerink Partnrs

Posted by Hanz Christensen on Feb 7th, 2025

Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Connect Biopharma in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($0.19) per share for the year. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.20) per share.

Connect Biopharma Stock Performance

Shares of NASDAQ:CNTB opened at $1.05 on Friday. The firm’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.15. Connect Biopharma has a fifty-two week low of $0.91 and a fifty-two week high of $2.66.

Institutional Investors Weigh In On Connect Biopharma

Several large investors have recently bought and sold shares of CNTB. Catalina Capital Group LLC acquired a new position in shares of Connect Biopharma in the 4th quarter valued at $66,000. Callan Capital LLC lifted its holdings in Connect Biopharma by 91.3% during the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after acquiring an additional 38,177 shares in the last quarter. Choreo LLC acquired a new position in Connect Biopharma in the fourth quarter valued at about $204,000. Finally, BML Capital Management LLC increased its holdings in shares of Connect Biopharma by 2.4% in the third quarter. BML Capital Management LLC now owns 2,093,232 shares of the company’s stock worth $3,014,000 after acquiring an additional 49,984 shares in the last quarter. Institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

(Get Free Report)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.